A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control
Interleukin-2 (IL-2) based cancer therapy is limited by severe toxicity and strong Treg amplification at the therapeutic dosage. Here, the authors develop a recombinant IL-2 immunocytokine which is comprised of a tumor-targeting antibody fused to a super mutant IL-2 and show in mouse models that thi...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d9466bada18644f1bed8cb45aa2a8e1a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:d9466bada18644f1bed8cb45aa2a8e1a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:d9466bada18644f1bed8cb45aa2a8e1a2021-12-02T17:02:15ZA next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control10.1038/s41467-019-11782-w2041-1723https://doaj.org/article/d9466bada18644f1bed8cb45aa2a8e1a2019-08-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-11782-whttps://doaj.org/toc/2041-1723Interleukin-2 (IL-2) based cancer therapy is limited by severe toxicity and strong Treg amplification at the therapeutic dosage. Here, the authors develop a recombinant IL-2 immunocytokine which is comprised of a tumor-targeting antibody fused to a super mutant IL-2 and show in mouse models that this next-generation IL2 has reduced toxicity and enhanced antitumor activity.Zhichen SunZhenhua RenKaiting YangZhida LiuShuaishuai CaoSisi DengLily XuYong LiangJingya GuoYingjie BianHairong XuJiyun ShiFan WangYang-Xin FuHua PengNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-12 (2019) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q Zhichen Sun Zhenhua Ren Kaiting Yang Zhida Liu Shuaishuai Cao Sisi Deng Lily Xu Yong Liang Jingya Guo Yingjie Bian Hairong Xu Jiyun Shi Fan Wang Yang-Xin Fu Hua Peng A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control |
| description |
Interleukin-2 (IL-2) based cancer therapy is limited by severe toxicity and strong Treg amplification at the therapeutic dosage. Here, the authors develop a recombinant IL-2 immunocytokine which is comprised of a tumor-targeting antibody fused to a super mutant IL-2 and show in mouse models that this next-generation IL2 has reduced toxicity and enhanced antitumor activity. |
| format |
article |
| author |
Zhichen Sun Zhenhua Ren Kaiting Yang Zhida Liu Shuaishuai Cao Sisi Deng Lily Xu Yong Liang Jingya Guo Yingjie Bian Hairong Xu Jiyun Shi Fan Wang Yang-Xin Fu Hua Peng |
| author_facet |
Zhichen Sun Zhenhua Ren Kaiting Yang Zhida Liu Shuaishuai Cao Sisi Deng Lily Xu Yong Liang Jingya Guo Yingjie Bian Hairong Xu Jiyun Shi Fan Wang Yang-Xin Fu Hua Peng |
| author_sort |
Zhichen Sun |
| title |
A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control |
| title_short |
A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control |
| title_full |
A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control |
| title_fullStr |
A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control |
| title_full_unstemmed |
A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control |
| title_sort |
next-generation tumor-targeting il-2 preferentially promotes tumor-infiltrating cd8+ t-cell response and effective tumor control |
| publisher |
Nature Portfolio |
| publishDate |
2019 |
| url |
https://doaj.org/article/d9466bada18644f1bed8cb45aa2a8e1a |
| work_keys_str_mv |
AT zhichensun anextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT zhenhuaren anextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT kaitingyang anextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT zhidaliu anextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT shuaishuaicao anextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT sisideng anextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT lilyxu anextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT yongliang anextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT jingyaguo anextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT yingjiebian anextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT hairongxu anextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT jiyunshi anextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT fanwang anextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT yangxinfu anextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT huapeng anextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT zhichensun nextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT zhenhuaren nextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT kaitingyang nextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT zhidaliu nextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT shuaishuaicao nextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT sisideng nextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT lilyxu nextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT yongliang nextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT jingyaguo nextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT yingjiebian nextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT hairongxu nextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT jiyunshi nextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT fanwang nextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT yangxinfu nextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol AT huapeng nextgenerationtumortargetingil2preferentiallypromotestumorinfiltratingcd8tcellresponseandeffectivetumorcontrol |
| _version_ |
1718381936966107136 |